A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

by | Jan 28, 2026 | Clinical Trials | 0 comments

​ Conditions: Moderate to Severe Asthma

Interventions: Drug: CM326; Other: Placebo

Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Not yet recruiting Conditions: Moderate to Severe Asthma
Interventions: Drug: CM326; Other: Placebo
Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *